Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
日本語
English
Русский
中文
Español
Português
Deutsch
한국어
Français
Italiano
Türkçe
OKYO
#6046
OKYO Pharma Limited Ordinary Shares
1.7
1
0.00%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
0.00%
Variazione Mensile
-23.32%
Variazione di 6 mesi
-24.67%
Variazione Annuale
+44.92%
Chiusura Precedente
1.7
1
Open
1.7
1
Bid
Ask
Low
1.7
1
High
1.7
1
Volume
2
Mercati
Mercato Azionario Statunitense
Salute
OKYO
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
37.61 M
—
Valuation ratios
Enterprise value
47.77 M
—
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
Notizie
Piper Sandler、OKYO Pharma株をOverweight評価でカバレッジ開始
Piper Sandler initiates OKYO Pharma stock with Overweight rating
OKYO Pharma社、2000万ドルの公募発表で株価急落
OKYO Pharma stock tumbles on $20 million public offering announcement
OKYO Pharma、普通株式の2000万ドル公募を発表
OKYO Pharma announces $20 million public offering of ordinary shares
OKYO Pharma、ATM株式募集のセールスエージェントをLeerink Partnersに移行
OKYO Pharma transitions ATM equity offering to Leerink Partners as sales agent
OKYO Pharmaが元Dompéの最高医療責任者フラビオ・マンテリを神経障害性角膜疼痛プログラム責任者に任命
OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program
OKYOファーマ、ASCRSミーティングでウルコシモドNCP研究結果を発表へ
OKYO Pharma to present urcosimod NCP study results at ASCRS meeting